Display options
Cite
Southgate HED, Chen L, Tweddle DA, et al. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051095.
Southgate, H. E. D., Chen, L., Tweddle, D. A., & Curtin, N. J. (2020). ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers, 12(5), . https://doi.org/10.3390/cancers12051095
Southgate, Harriet E D, et al. "ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051095
Southgate HED, Chen L, Tweddle DA, Curtin NJ. ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms. Cancers (Basel). 2020 Apr 28;12(5). doi: 10.3390/cancers12051095. PMID: 32354033; PMCID: PMC7281288.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Apr 28;12(5). doi: 10.3390/cancers12051095.

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.

Cancers

Harriet E D Southgate, Lindi Chen, Deborah A Tweddle, Nicola J Curtin

Affiliations

  1. Wolfson Childhood Cancer Research Centre, Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE1 7RU, UK.
  2. Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK.

PMID: 32354033 PMCID: PMC7281288 DOI: 10.3390/cancers12051095

[No abstract available.]

Keywords: ataxia telangiectasia and Rad3 related inhibitors (ATRi); cell cycle checkpoints; poly (ADP-ribose) polymerase inhibitors (PARPi); replication stress

References

  1. Mol Cell. 2017 Jun 15;66(6):735-749 - PubMed
  2. J Cell Biol. 2007 Mar 12;176(6):749-55 - PubMed
  3. Annu Rev Genet. 2016 Nov 23;50:155-173 - PubMed
  4. Nucleic Acids Res. 2006;34(19):5603-12 - PubMed
  5. Oncotarget. 2015 Oct 20;6(32):32396-409 - PubMed
  6. Clin Cancer Res. 2015 Nov 1;21(21):4780-5 - PubMed
  7. Nat Rev Cancer. 2003 Mar;3(3):203-16 - PubMed
  8. Cell Cycle. 2006 Nov;5(22):2639-47 - PubMed
  9. Br J Cancer. 2016 Oct 25;115(9):1048-1057 - PubMed
  10. Science. 2017 Mar 17;355(6330):1152-1158 - PubMed
  11. Cancer Res. 2012 Nov 1;72(21):5588-99 - PubMed
  12. J Clin Oncol. 2009 Jan 10;27(2):289-97 - PubMed
  13. Clin Cancer Res. 2010 Apr 15;16(8):2344-51 - PubMed
  14. Mol Cancer Ther. 2017 Apr;16(4):566-577 - PubMed
  15. Mol Cell. 2017 Jun 15;66(6):801-817 - PubMed
  16. EMBO J. 2009 Sep 2;28(17):2601-15 - PubMed
  17. Clin Cancer Res. 2009 Feb 15;15(4):1241-9 - PubMed
  18. J Clin Oncol. 2010 May 20;28(15):2625-34 - PubMed
  19. Mol Cancer. 2017 Jun 29;16(1):114 - PubMed
  20. Am J Pathol. 2003 Jul;163(1):321-31 - PubMed
  21. Nat Struct Mol Biol. 2011 Nov 27;18(12):1331-1335 - PubMed
  22. Oncotarget. 2016 Nov 22;7(47):76534-76550 - PubMed
  23. Cell Cycle. 2013 Jun 15;12(12):1826-7 - PubMed
  24. Br J Cancer. 2011 Jul 26;105(3):372-81 - PubMed
  25. PLoS One. 2015 May 12;10(5):e0125482 - PubMed
  26. Nat Struct Mol Biol. 2011 Jun;18(6):721-7 - PubMed
  27. Cancer Res. 2006 Feb 15;66(4):2138-45 - PubMed
  28. J Cell Biol. 2017 Oct 2;216(10):3097-3115 - PubMed
  29. Mol Cell. 2017 Jan 19;65(2):336-346 - PubMed
  30. Clin Cancer Res. 2017 Jun 15;23(12):3097-3108 - PubMed
  31. Nat Rev Genet. 2008 Aug;9(8):619-31 - PubMed
  32. Oncogene. 2017 Aug 17;36(33):4682-4691 - PubMed
  33. Genes Chromosomes Cancer. 2001 Oct;32(2):126-35 - PubMed
  34. Nat Rev Mol Cell Biol. 2017 Oct;18(10):622-636 - PubMed
  35. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1506-11 - PubMed
  36. Genes Dev. 2017 Feb 1;31(3):318-332 - PubMed
  37. Cancer Res. 1995 Apr 15;55(8):1639-42 - PubMed
  38. Genes Chromosomes Cancer. 2006 May;45(5):495-508 - PubMed
  39. Cancers (Basel). 2018 Aug 20;10(8): - PubMed
  40. Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4323-8 - PubMed
  41. Oncotarget. 2016 Jul 19;7(29):46203-46218 - PubMed
  42. Nat Commun. 2019 Feb 22;10(1):910 - PubMed
  43. Nucleic Acids Res. 2012 Nov;40(21):10780-94 - PubMed
  44. Cell Death Dis. 2018 Aug 30;9(9):895 - PubMed
  45. J Natl Cancer Inst. 2017 Nov 1;109(11): - PubMed
  46. Cancer Discov. 2018 May;8(5):537-555 - PubMed
  47. Mol Cancer Ther. 2014 Jun;13(6):1645-54 - PubMed
  48. Nat Rev Cancer. 2018 Sep;18(9):586-595 - PubMed
  49. Future Oncol. 2016 Jan;12(2):221-37 - PubMed
  50. Blood. 2016 Feb 4;127(5):582-95 - PubMed
  51. Cancer Res. 2017 Jun 1;77(11):3040-3056 - PubMed
  52. Oncotarget. 2015 Jul 30;6(21):18558-76 - PubMed
  53. Am J Pathol. 1996 May;148(5):1381-5 - PubMed
  54. Nat Chem Biol. 2011 Apr 13;7(7):428-30 - PubMed
  55. J Clin Invest. 2012 Jan;122(1):241-52 - PubMed
  56. Cancer Res. 2007 Nov 1;67(21):10351-60 - PubMed
  57. J Cell Sci. 2018 Jun 25;131(12): - PubMed
  58. Mol Cancer Ther. 2018 Nov;17(11):2462-2472 - PubMed
  59. Nature. 2004 Nov 18;432(7015):298-306 - PubMed
  60. Clin Cancer Res. 2010 Feb 15;16(4):1108-18 - PubMed
  61. Pediatr Blood Cancer. 2013 Jun;60(6):985-93 - PubMed
  62. BMC Cancer. 2016 Aug 11;16:621 - PubMed
  63. Nat Cell Biol. 2014 Jan;16(1):2-9 - PubMed
  64. Pediatr Blood Cancer. 2014 Jan;61(1):145-50 - PubMed
  65. J Natl Cancer Inst. 1983 Oct;71(4):741-7 - PubMed
  66. Cancer Res. 1970 Aug;30(8):2110-8 - PubMed
  67. Clin Cancer Res. 2017 Nov 15;23(22):6875-6887 - PubMed

Publication Types

Grant support